Loren Decarlo, DO
Family Medicine · Capac, MINPI 1629003462
Payments from drug & device makers
Across 296 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$598
- Lilly USA, LLC$518
- Boehringer Ingelheim$437
- AstraZeneca$349
- AbbVie$348
- Amgen$271
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,764100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $598 |
| Lilly USA, LLC | 34 | $518 |
| Boehringer Ingelheim | 21 | $437 |
| AstraZeneca(2 entities) | 20 | $349 |
| AbbVie(2 entities) | 24 | $348 |
| Amgen | 17 | $271 |
| GSK | 17 | $257 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $241 |
| Merck | 12 | $194 |
| Otsuka America Pharmaceutical, Inc. | 9 | $169 |
| Sanofi-aventis U.S. LLC | 8 | $159 |
| Pfizer | 11 | $157 |
| Amarin Pharma, Inc. | 9 | $149 |
| Bayer | 7 | $130 |
| Exact Sciences | 6 | $116 |
| Johnson & Johnson | 6 | $108 |
| Astellas Pharma US Inc | 7 | $95 |
| Novartis | 5 | $67 |
| Dexcom, Inc. | 3 | $60 |
| Acadia Pharmaceuticals Inc | 2 | $56 |
| Corcept Therapeutics | 2 | $46 |
| Supernus Pharmaceuticals, Inc. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Lundbeck LLC | 1 | $30 |
| Sanofi | 1 | $26 |
| Verona Pharma, Inc. | 1 | $24 |
| Tris Pharma Inc | 2 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Abbott | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Indivior Inc. | 1 | $15 |
How this compares
$4,777 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 123 | $137,470 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $86,807 |
| JanuviaSitagliptin Phosphate | 53 | $75,407 |
| JardianceEmpagliflozin | 54 | $66,171 |
| OzempicSemaglutide | 30 | $64,315 |
| MounjaroTirzepatide | 56 | $62,484 |
| MyrbetriqMirabegron | 24 | $27,568 |
| XareltoRivaroxaban | 18 | $26,741 |
| RybelsusSemaglutide | 15 | $23,835 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $10,692 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $10,194 |
| Mirabegron ErMirabegron | 11 | $8,846 |
| Novolog FlexpenInsulin Aspart | 19 | $8,104 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $7,822 |
| DuleraMometasone/Formoterol | 14 | $7,711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $157 | $137,470123 claims |
| Novo NordiskOzempic, Rybelsus | $598 | $88,15045 claims |
| GSKTrelegy Ellipta | $257 | $86,80781 claims |
| MerckJanuvia, Dulera | $194 | $83,11867 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $437 | $73,99367 claims |
| Lilly USA, LLCMounjaro | $518 | $62,48456 claims |
| Astellas Pharma US IncMyrbetriq | $95 | $27,56824 claims |
| Johnson & JohnsonXarelto | $108 | $26,74118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Capac
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.